Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

计划入组 38 人 · 首次发布于 2010 年 4 月 9 日

Neoadjuvant Tebentafusp for Uveal Melanoma

计划入组 19 人 · 首次发布于 2024 年 5 月 16 日

Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

计划入组 30 人 · 首次发布于 2026 年 8 月 5 日

aptamer-drug conjugate (uveal melanoma)

melanoma vaccine

Melanoma(FAKnostics)

MELANOMA INSTITUTE AUSTRALIA

Australia

PRIMARY PHARMACEUTICALS, INC.

United States

PRIMARY HEALTH CARE CORPORATION

Qatar

IDEAYA Biosciences to Present Phase 2 Darovasertib Data for Uveal Melanoma at ESMO 2025

Phase 3 Trial Initiates to Evaluate Kimmtrak in Non-Metastatic Uveal Melanoma

Servier and IDEAYA Biosciences Strike $530M Partnership for Uveal Melanoma Drug Darovasertib